Genprex Inc. Stock News

The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.

The stock price of Genprex Inc (NASDAQ: GNPX) increased by 167.18% in the most recent trading session. This is why it happened.

Genprex Inc (NASDAQ: GNPX) is a clinical-stage gene therapy organization that concentrates on the development of life-changing gene therapies to treat people with diabetes and cancer. The company ann

Shares of Genprex Inc. GNPX, +121.37% skyrocketed 121% on massive volume in afternoon trading Monday, after the gene therapy company said its Reqorsa Immunogene Therapy was granted Fast Track Designat

Shares of GNPX stock are soaring higher after the FDA granted fast track designation (FTD) for the company's lead drug candidate, REQORSA. The post GNPX Stock: 5 Things to Know as Genprex Rockets High

We're diving into the top penny stocks to watch today as several names in the space see major movement on Monday alongside heavy trading. The post 8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT,

Genprex Inc (NASDAQ: GNPX) is trading higher Monday after the company announced it received U.S. Food and Drug Administration Fast Track Designation (FTD) for REQORSA Immunogene Therapy in combinati

Focused on developing life-changing therapies for patients with cancer and diabetes  Advancing lead product REQORSA immunogene therapy for non-small cell lung cancer Struck licensing agreement with

Genprex, Inc. (NASDAQ:GNPX) revealed that the US Food and Drug Administration (FDA) granted Fast Track designation to the company's lead drug candidate, REQORSA Immunogene Therapy, in combination wit

The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation covers Reqorsa combined with Merck & Co Inc

Geode Capital Management LLC lowered its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 34.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 358,625 shares of the companys stock after selling 188,294 shares during the quarter. Geode Capital Management LLCs []

GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes.

AUSTIN, Texas--(BUSINESS WIRE)--Genprex''s CEO will present on November 17 at 11 a.m. ET with CEO Roadshow.